21-Hydroxylase Deficiency screening: Difference between revisions
(Created page with "__NOTOC__ {{21-Hydroxylase Deficiency}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Disease Category:Endocrinology and Metabolic Disease [...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
===Newborn screening=== | |||
Conditions justifying [[newborn screening]] for any disorder include (1) a simple test with an acceptable [[Sensitivity (tests)|sensitivity]] and [[Specificity (tests)|specificity]], (2) a dire consequence if not diagnosed early, (3) an effective treatment if diagnosed, and (4) a frequency in the population high enough to justify the expense. In the last decade more states and countries are adopting newborn screening for salt-wasting CAH due to 21-hydroxylase deficiency, which leads to death in the first month of life if not recognized. | |||
The salt-wasting form of CAH has an incidence of 1 in 15,000 births, is potentially fatal within a month if untreated, and steroid replacement is a simple, effective treatment. However, the screening test itself is less than perfect. While the [[17-hydroxyprogesterone|17OHP]] level is easy to measure and sensitive (rarely missing real cases), the test has a poorer specificity. Screening programs in the United States have reported that 99% of positive screens turn out to be false positives upon investigation of the infant. This is a higher rate of false positives than the screening tests for many other [[congenital metabolic disease]]s. While each screen costs less than US$2, the program costs well over US$100,000 for each case detected. | |||
When a positive result is detected, the infant's family and doctor must be notified, and the infant must be referred to a pediatric endocrinologist to confirm or disprove the diagnosis. Since most infants with salt-wasting CAH become critically ill by 2 weeks of age, the evaluation must be done rapidly despite the high false positive rate. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 17:10, 19 September 2012
Template:21-Hydroxylase Deficiency Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Newborn screening
Conditions justifying newborn screening for any disorder include (1) a simple test with an acceptable sensitivity and specificity, (2) a dire consequence if not diagnosed early, (3) an effective treatment if diagnosed, and (4) a frequency in the population high enough to justify the expense. In the last decade more states and countries are adopting newborn screening for salt-wasting CAH due to 21-hydroxylase deficiency, which leads to death in the first month of life if not recognized.
The salt-wasting form of CAH has an incidence of 1 in 15,000 births, is potentially fatal within a month if untreated, and steroid replacement is a simple, effective treatment. However, the screening test itself is less than perfect. While the 17OHP level is easy to measure and sensitive (rarely missing real cases), the test has a poorer specificity. Screening programs in the United States have reported that 99% of positive screens turn out to be false positives upon investigation of the infant. This is a higher rate of false positives than the screening tests for many other congenital metabolic diseases. While each screen costs less than US$2, the program costs well over US$100,000 for each case detected.
When a positive result is detected, the infant's family and doctor must be notified, and the infant must be referred to a pediatric endocrinologist to confirm or disprove the diagnosis. Since most infants with salt-wasting CAH become critically ill by 2 weeks of age, the evaluation must be done rapidly despite the high false positive rate.